Opsona's research
The recent scientific literature suggests that tackling the initiating pathways of the innate immune system, e.g. the Toll-Like Receptors (TLRs) and the inflammasome, may lead to improved drugs for the treatment and prevention of autoimmune & inflammatory diseases.
Opsona has the expertise, people, products and partnerships to tackle this system using highly targeted approaches.
Opsona has strong links to leading academic centres throughout Europe and the US, giving us access to emerging technologies which have a significant impact in the field. We pride ourselves on our ability to work closely and collaborate with academic and industry partners to identify key discoveries and develop new drugs together.